- Home
- BST vs INBX Comparison
BST vs INBX Comparison
Compare BST & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BST | INBX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BST | INBX |
|---|---|---|
| Price | $48.40 | $92.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 121.7K | ★ 266.0K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $34.87 | $13.97 |
| 52 Week High | $50.56 | $155.29 |
Technical Indicators
Market Signals| Indicator | BST | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 43.53 |
| Support Level | $38.90 | $71.31 |
| Resistance Level | $50.56 | $94.52 |
| Average True Range (ATR) | 1.42 | 6.37 |
| MACD | -0.18 | 0.11 |
| Stochastic Oscillator | 60.24 | 38.60 |
Price Performance
Historical ComparisonAbout BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.